Amgen (AMGN)
(Delayed Data from NSDQ)
$286.30 USD
+4.53 (1.61%)
Updated Mar 27, 2024 04:00 PM ET
After-Market: $286.43 +0.13 (0.05%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth C Momentum C VGM
Amgen (AMGN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$309.90 | $380.00 | $185.00 | 8.24% |
Price Target
Based on short-term price targets offered by 21 analysts, the average price target for Amgen comes to $309.90. The forecasts range from a low of $185.00 to a high of $380.00. The average price target represents an increase of 8.24% from the last closing price of $286.30.
Analyst Price Targets (21)
Broker Rating
Amgen currently has an average brokerage recommendation (ABR) of 2.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 24 brokerage firms. The current ABR compares to an ABR of 2.13 a month ago based on 24 recommendations.
Of the 24 recommendations deriving the current ABR, 12 are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 50% and 4.17% of all recommendations. A month ago, Strong Buy made up 50%, while Buy represented 4.17%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 11 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 9 | 9 | 9 | 8 | 8 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 2 | 2 | 2 | 2 | 2 |
ABR | 2.13 | 2.13 | 2.13 | 2.09 | 2.14 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
2/7/2024 | SVB Securities | David Risinger | Strong Buy | Hold |
2/7/2024 | Piper Sandler | Christopher Raymond | Strong Buy | Strong Buy |
12/21/2023 | Daiwa America | Narumi Nakagiri | Not Available | Strong Buy |
12/19/2023 | BMO Capital Markets | Evan Seigerman | Hold | Strong Buy |
11/29/2023 | Truist Securities | Robyn Karnauskas | Strong Buy | Strong Buy |
11/3/2023 | William Blair | Matt Phipps | Hold | Hold |
10/17/2023 | Argus Research Corp. | David A Toung | Strong Buy | Strong Buy |
8/14/2023 | Mizuho SecuritiesUSA | Salim Syed | Hold | Hold |
8/3/2023 | Not Identified | Not Identified | Hold | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.13 |
ABR (Last week) | 2.13 |
# of Recs in ABR | 24 |
Average Target Price | $309.90 |
LT Growth Rate | 5.40% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | 3.84 |